Rita Maalouf

Dr. Rita Maalouf

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in TrAC Trends in Analytical Chemistry
Verified
Journal Article
Closed access
SSSimona Sawan
Simona Sawan
RMRita Maalouf
Rita Maalouf
AEAbdelhamid Errachid
Abdelhamid Errachid
Nicole Jaffrezic-RenaultNicole Jaffrezic-Renault
Nicole Jaffrezic-Renault

1 February 2012 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Open access
PDF file
RMRita Maalouf
Rita Maalouf
AEAssaad A. Eid
Assaad A. Eid
YGYves C. Gorin
Yves C. Gorin
KBKaren Block
Karen Block
GEGladys Patricia Escobar
Gladys Patricia Escobar
HAHanna E. Abboud
Hanna E. Abboud
Oxidative stress contributes to diabetic cardiomyopathy. This study explored the role of the NADPH oxidase Nox4 as a source of reactive oxygen species (ROS) involved in the development of diabetic cardiomyopathy. Phosphorothioated antisense (AS) or sense (S) oligonucleotides for Nox4 were administered for 2 wk to rats made diabetic by streptozotocin. NADPH oxidase activity, ROS generation, and the expression of Nox4, but Nox1 or Nox2, were increased in left ventricular tissue of the diabetic rats. Expression of molecular markers of hypertrophy and myofibrosis including fibronectin, collagen, α-smooth muscle actin, and β-myosin heavy chain were also increased. These parameters were attenuated by the administration of AS but not S Nox4. Moreover, the impairment of contractility observed in diabetic rats was prevented in AS- but not S-treated animals. Exposure of cultured cardiac myocytes to 25 mM glucose [high glucose (HG)] increased NADPH oxidase activity, the expression of Nox4, and molecular markers of cardiac injury. These effects of HG were prevented in cells infected with adenoviral vector containing a dominant negative form of Nox4. This study provides strong evidence that Nox4 is an important source of ROS in the left ventricle and that Nox4-derived ROS contribute to cardiomyopathy at early stages of type 1 diabetes.

15 March 2016 in Heart Failure Reviews
Verified
Journal Article
Open access
PDF file
RMRita Maalouf
Rita Maalouf
SBSteven Bailey
Steven Bailey
Since its discovery in 1988, B-type natriuretic peptide (BNP) has been recognized as a powerful cardiovascular biomarker for a number of disease states, specifically heart failure. Concurrent with such a discovery, much effort has been allocated to the precise monitoring of physiological BNP levels. Thus, it can be used to guide the therapy of heart failure and determine the patient’s stage of disease. Thus, we discuss in this article BNP as a potent biomarker. Subsequently, we will review the progress of biosensing devices as they could be applied to monitor BNP levels as assays, benchtop biosensors and implantable biosensors. The analytical characteristics of commercially available BNP assays are presented. Still emerging as a field, we define four obstacles that present opportunity for the future development of implantable biosensor: foreign body response, sensor renewability, sensitivity and selectivity.

6 December 2016 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
AJAntranik Jonderian
Antranik Jonderian
RMRita Maalouf
Rita Maalouf
This study aims to characterize rhodamine B (Rh B) loaded poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles (NPs) and their interactions with cardiac myocytes. PLGA NPs were formulated using single emulsion solvent evaporation technique. The influence of varying parameters such as the stabilizer concentration, the sonication time, and the organic to aqueous ratio were investigated. The diameter, the dispersity, the encapsulation efficiency and the zeta potential of the optimized nanoparticles were about 184 nm, 0.19, 40% and -21.7 mV respectively. In vitro release showed that 29% of the Rh B was released within the first 8 hours. Scanning electron microscopy (SEM) measurements performed on the optimized nanoparticles showed smooth surface and spherical shapes. No significant cytotoxic or apoptotic effects were observed on fetal cardiac myocytes after 24 and 48 hours of exposure with concentrations up to 200 µg/mL. The kinetic of the intracellular uptake was confirmed by confocal microscopy and cells took up PLGA NPs within the first hours. Interestingly, our data show an increase in the nanoparticles’ uptake with time of exposure. Taken together, we demonstrate for the first time that the designed NPs can be used as potential probes for drug delivery in cardiac myocytes.

1 January 2019 in Frontiers in Bioscience-Scholar
Verified
Journal Article
Closed access
JMJihane Matta
Jihane Matta
RMRita Maalouf
Rita Maalouf
RNA interference is currently one of the most advanced genomic tools providing promising insight to manage countless pathophysiological conditions that seemed unapproachable few years ago. Researchers across the globe have devised numerous methods in which small RNA molecules can be administered into target cells to manipulate cellular functions at the molecular level and eradicate defects that lead to pronounced phenotypes, which might sometimes be as fatal as malignant tumors. The present review provides an overview of the non-viral delivery approaches for siRNA therapeutics with an emphasis on the PLGA polymeric strategy and its use in different biological applications. Due to its versatile surface, PLGA is not only used in tissue engineering such as remodeling of bone and cartilage, but it indeed plays a crucial role as chemical carrier for a broad range of therapeutic agents. It is greatly implicated in gene therapies and inherited genetic defects.

31 December 2024 in Microchemical Journal
Verified
Journal Article
Closed access
RKRania Al Kaassamani
Rania Al Kaassamani
SSSimona Sawan
Simona Sawan
Nicole Jaffrezic-RenaultNicole Jaffrezic-Renault
Nicole Jaffrezic-Renault
RMRita Maalouf
Rita Maalouf